» Articles » PMID: 34517415

How I Manage Autoimmune Cytopenias in Patients with Lymphoid Cancer

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2021 Sep 13
PMID 34517415
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune conditions can occur in a temporary relationship with any malignant lymphoma. In many instances, treatment at diagnosis is not required, but symptomatic autoimmune conditions represent an indication for treatment, particularly in chronic lymphoproliferative diseases. Treatment is selected depending on the predominant condition: autoimmune disease (immunosuppression) or lymphoma (antilymphoma therapy). Steroids and anti-CD20 antibodies are effective against both conditions and may suppress the autoimmune complication for a prolonged period. The efficacy of B-cell receptor inhibitors has provided us with novel insights into the pathophysiology of antibody-producing B cells. Screening for underlying autoimmune conditions is part of the lymphoma workup, because other drugs, such as immunomodulators and checkpoint inhibitors, should be avoided or used with caution. In this article, we discuss diagnostic challenges and treatment approaches for different situations involving lymphomas and autoimmune cytopenias.

Citing Articles

Mendelian randomization analysis reveals causal effects of inflammatory bowel disease and autoimmune hyperthyroidism on diffuse large B-cell lymphoma risk.

Lyu C, Wang Y, Xu R Sci Rep. 2024; 14(1):29163.

PMID: 39587169 PMC: 11589711. DOI: 10.1038/s41598-024-79791-4.


Shared genetic architecture between autoimmune disorders and B-cell acute lymphoblastic leukemia: insights from large-scale genome-wide cross-trait analysis.

Yu X, Chen Y, Chen J, Fan Y, Lu H, Wu D BMC Med. 2024; 22(1):161.

PMID: 38616254 PMC: 11017616. DOI: 10.1186/s12916-024-03385-0.


The Role of the Spleen and the Place of Splenectomy in Autoimmune Hemolytic Anemia-A Review of Current Knowledge.

Cvetkovic Z, Pantic N, Cvetkovic M, Virijevic M, Sabljic N, Marinkovic G Diagnostics (Basel). 2023; 13(18).

PMID: 37761258 PMC: 10527817. DOI: 10.3390/diagnostics13182891.


Chronic lymphocytic leukemia treatment algorithm 2022.

Hampel P, Parikh S Blood Cancer J. 2022; 12(11):161.

PMID: 36446777 PMC: 9708674. DOI: 10.1038/s41408-022-00756-9.

References
1.
Arthold C, Skrabs C, Mitterbauer-Hohendanner G, Thalhammer R, Simonitsch-Klupp I, Panzer S . Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings. Wien Klin Wochenschr. 2014; 126(11-12):376-82. DOI: 10.1007/s00508-014-0547-z. View

2.
Berentsen S, Ulvestad E, Gjertsen B, Hjorth-Hansen H, Langholm R, Knutsen H . Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004; 103(8):2925-8. DOI: 10.1182/blood-2003-10-3597. View

3.
Nader K, Patel M, Ferber A . Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2013; 13(4):511-3. DOI: 10.1016/j.clml.2013.02.022. View

4.
Crickx E, Poullot E, Moulis G, Goulabchand R, Fieschi C, Galicier L . Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. Eur J Haematol. 2019; 103(1):35-42. DOI: 10.1111/ejh.13239. View

5.
Montillo M, OBrien S, Tedeschi A, Byrd J, Dearden C, Gill D . Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer J. 2017; 7(2):e524. PMC: 5386339. DOI: 10.1038/bcj.2017.5. View